A six-week randomized trial demonstrated that daily almond consumption by adults with obesity improved inflammatory cytokine profiles and overall diet quality, independently of weight loss.
The study, published in Nutrients, investigated the impact of daily almond consumption on systemic markers of inflammation and immunity in middle-aged adults with obesity.
Obesity is characterized by chronic low-grade systemic inflammation, involving increased pro-inflammatory cytokines and altered innate immune cell populations. This sustained inflammatory response is linked to insulin resistance, type 2 diabetes, and cardiovascular disease. Dietary modifications, such as the Mediterranean diet, have been shown to reduce obesity-related systemic inflammation. Nuts, including almonds, are key components of high-quality dietary patterns and are rich in monounsaturated fats, vitamin E, zinc, magnesium, and polyphenols.
Daily almond consumption by adults with obesity improved inflammatory cytokine profiles and overall diet quality, independently of weight loss.
Methodology
The trial was designed to assess the effects of regular almond intake.
- Participants: 69 generally healthy adults with obesity (BMI 30–45 kg/m²), aged 30–45 years, were enrolled.
- Intervention: Participants were randomized to consume either whole almonds or an isocaloric amount of cookies daily for six weeks. No additional dietary counseling was provided.
- Design: The trial used a single-blind design, ensuring participants were unaware of their group assignment.
- Outcomes: Primary outcomes focused on immune and inflammatory markers. Secondary outcomes included body measurements, cardiovascular data, dietary intake, and appetite. Measurements were taken before and after the intervention period, assessing specific markers like glucose, lipid profiles, insulin, TNF-alpha, IFN-gamma, IL-6, and IL-10.
Key Findings
The six-week intervention yielded several important results regarding health markers and dietary habits.
Body Metrics and Lipid Profile
No significant differences were observed between the almond and cookie groups in body weight, waist/hip circumferences, blood pressure, serum glucose, insulin, or insulin sensitivity/resistance after six weeks. However, high-density lipoprotein cholesterol (HDL-C) was higher in the almond group at week 6, primarily due to a slight decline in the cookie group.
Compliance and Palatability
Both groups maintained remarkably high compliance (almond: 93.9%, cookie: 92.5%). Interestingly, almonds were rated as more acceptable than cookies. No significant differences in hunger, desire to eat, or fullness ratings were found between groups.
Dietary Quality Improvements
The almond group exhibited higher intakes of healthy fats (monounsaturated fatty acids and oleic acid), fiber, and certain vitamins and minerals. They also showed improved dietary pattern scores and lower refined grain intake compared to the cookie group. Vitamin E intake specifically increased in the almond group.
Impact on Inflammatory Markers
Baseline-adjusted concentrations of inflammatory cytokines, specifically IL-6, TNF-alpha, and IFN-gamma, were lower in the almond group at week 6 compared to the cookie group. An increase in the anti-inflammatory marker IL-10 was also greater in the almond group, though these results are subject to cautious interpretation given the study's relatively small sample size and short duration.
Conclusion and Future Research
Daily almond consumption was associated with improvements in inflammatory cytokine profiles and overall diet quality among middle-aged adults with obesity, without significant weight loss. These findings suggest that incorporating almonds into daily meals may help improve inflammatory biomarker profiles associated with obesity and promote better nutritional habits. Future research should investigate the long-term benefits of almonds, their effects across diverse populations, and the underlying mechanisms influencing inflammatory pathways.